CHICAGO, July 11, 2024 /PRNewswire/ -- The
global GLP-1 analogues market is poised for substantial
growth, projected to expand from USD 47.4
billion in 2024 to USD 471.1
billion by 2032, at a robust CAGR of 33.2%. Key drivers
include the drugs' efficacy in managing diabetes and obesity,
driving high demand and clinical research advancements. The market
is dominated by two major players, Novo Nordisk A/S and Eli Lilly
and Company, creating significant entry barriers. Opportunities lie
in expanding therapeutic applications beyond diabetes to include
conditions like NASH and Alzheimer's disease. However, challenges
such as patient non-adherence and the dominance of injectable
formats hinder market growth. North
America leads in market share, supported by accessibility
and demand for GLP-1 analogues. Key players like Novo Nordisk, Eli
Lilly, Sanofi, and AstraZeneca are pivotal in shaping market
dynamics through extensive R&D and strategic expansions.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218746186
Browse in-depth TOC on "GLP-1 Analogues
Market".
405 - Tables
59 - Figures
315 -
Pages
Ozempic Leads the Charge in the GLP-1 Analogue Market
In 2023, Ozempic (semaglutide) dominated the GLP-1 Analogue
market, buoyed by its significant revenue contribution and broad
global application for diabetes treatment. Its market presence
extends to obesity treatment under the brand Wegovy in Brazil, with a notable growth rate of
approximately 70% from 2019 to 2023. Such robust performance
underscores Ozempic's pivotal role in driving market expansion
throughout the forecast period.
Single-Dose Formats Propel Growth in GLP-1 Analogue
Adoption
The single-dose segment held the largest share of the GLP-1
Analogue market in 2023, a trend expected to persist. This
dominance is attributed to the convenience and enhanced adherence
facilitated by products like WEGOVY and TRULICITY, which offer
comfortable weekly self-administration via autoinjectors. These
advantages are set to bolster the segment's growth moving
forward.
Subcutaneous Administration Commands Market
Preference
In 2023, subcutaneous administration accounted for the largest
market share in the GLP-1 Analogue segment, leveraging its ability
to bypass gastrointestinal adverse effects and deliver rapid
therapeutic effects. This preference is bolstered by the
availability of diverse injector types, including pen injectors and
autoinjectors, catering to varied patient needs.
Diabetes Indication Spearheads GLP-1 Analogue Market
The diabetes indication segment emerged as the largest in the
GLP-1 Analogue market in 2023, driven by increasing demand for
effective Type-2 Diabetes management. This growth is further
supported by a robust research and development pipeline focusing on
enhancing therapeutic outcomes compared to other antidiabetic drug
classes.
Home Care Settings Drive GLP-1 Analogue Adoption
Home care settings dominated the GLP-1 Analogue market in 2023,
facilitated by the convenience and patient adherence advantages
offered by at-home drug administration. This trend is augmented by
the expanding utilization of GLP-1 Analogue drugs in treating
obesity outside traditional healthcare facilities.
North America Poised for Significant Growth in GLP-1 Analogue
Market
North America, particularly the
US, is expected to exhibit the highest growth rate in the GLP-1
Analogue market during the forecast period. This projection stems
from increasing adoption of GLP-1 drugs for diabetes and obesity
treatment, supported by well-established healthcare infrastructure
and favorable reimbursement frameworks.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=218746186
Dominance of Novo Nordisk A/S in the GLP-1 Analogue
Market
Novo Nordisk A/S (Denmark)
stands as a pivotal force in the GLP-1 Analogue market, boasting a
diverse product portfolio highlighted by flagship products like
Ozempic and Wegovy. The company's extensive global distribution
channels and robust R&D efforts underscore its leadership in
insulin and GLP-1 manufacturing worldwide. Novo Nordisk's focus on
developing oral formulations of existing GLP-1 drugs further
enhances patient convenience and therapeutic efficacy.
Eli Lilly and Company's Strategic Expansion in GLP-1 Analogue
Market
Eli Lilly and Company (US) plays a prominent role in advancing
the GLP-1 Analogue market, with significant investments exceeding
USD 9 billion in R&D during 2023
alone. The company's commercialized products, including Mounjaro,
Trulicity, and Zepbound, contribute substantially to its revenue,
with Trulicity and Mounjaro jointly accounting for approximately
36% of total earnings in 2023. Eli Lilly's ongoing focus on
expanding its clinical pipeline reinforces its competitive position
in the market.
Sanofi's Global Presence and Regulatory Advancements
Sanofi (France) maintains a
strong foothold in the GLP-1 Analogue market through products like
Soliqua, marketed in over 80 countries worldwide. The company's
strategic approach includes securing regulatory approvals across
diverse geographies, exemplified by recent approvals in
China for Soliqua to enhance
glycemic control in adults with type 2 diabetes. Sanofi's expansive
geographic reach and rigorous regulatory strategies position it as
a key player driving market growth and accessibility.
For more information, inquire now! Inquire Now
Related Reports:
Active Pharmaceutical Ingredient Market
Healthcare Analytical Testing Services Market
Mice Model Market
Digital Therapeutics Market
Pen Needles Market
Get access to the latest updates on GLP-1 Analogues
Companies and GLP-1 Analogues Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's
best management consulting firms by Forbes, as per their recent
report.
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine
offering to drive supernormal growth for progressive organizations
in the B2B space. We have the widest lens on emerging technologies,
making us proficient in co-creating supernormal growth for
clients.
Earlier this year, we made a formal transformation into one of
America's best management consulting firms as per a survey
conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are
substituting existing revenue streams in this decade alone. We work
with clients on growth programs, helping them monetize this
$25 trillion opportunity through our
service lines - TAM Expansion, Go-to-Market (GTM) Strategy to
Execution, Market Share Gain, Account Enablement, and Thought
Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a
disruptive ecosystem. Our insights and strategies are molded by our
industry experts, cutting-edge AI-powered Market Intelligence
Cloud, and years of research. The KnowledgeStore™ (our Market
Intelligence Cloud) integrates our research, facilitates an
analysis of interconnections through a set of applications, helping
clients look at the entire ecosystem and understand the revenue
shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us
on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan
Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo:
https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/glp-1-analogues-market-forecast-usd-471-1-billion-by-2032-with-a-33-2-cagr--marketsandmarkets-302194545.html